5-(methylsulfonyl)-1-(5-((1-(4-(trifluoromethyl)benzyl)piperidin-4-yl)oxy)pyridin-2-yl)-1H-indole | 1379529-69-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 5-(methylsulfonyl)-1-(5-((1-(4-(trifluoromethyl)benzyl)piperidin-4-yl)oxy)pyridin-2-yl)-1H-indole
• 英文别名: 5-Methylsulfonyl-1-[5-[1-[[4-(trifluoromethyl)phenyl]methyl]piperidin-4-yl]oxypyridin-2-yl]indole
• CAS: 1379529-69-7
• 化学式: C₂₇H₂₆F₃N₃O₃S
• 分子量: 529.583
• InChiKey: PZAKLUWWLXQMRK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  37
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  72.8
• 氢给体数：
  0
• 氢受体数：
  8

文献信息

• [EN] BICYCLIC GPR119 MODULATORS<br/>[FR] MODULATEURS DE GPR119 BICYCLIQUES
  申请人：LUPIN LTD

  公开号：WO2012069917A1

  公开（公告）日：2012-05-31

  The present invention relates to compounds of Formula (I) that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of GPR119 receptor activity. The invention also relates to the process for preparation of the compounds, pharmaceutical compositions thereof. The invention further relates to methods of treating, preventing and/or managing diseases, disorders syndromes or conditions associated with the modulation of GPR1 19 receptor by using either alone or in combinations of Formula (I).

  本发明涉及一种化合物（I）的公式，该化合物对治疗、预防和/或管理与调节GPR119受体活性相关的疾病、紊乱、综合征或病况有用。该发明还涉及制备这些化合物的方法、其药物组成物。此外，该发明还涉及利用单独或以公式（I）的组合物治疗、预防和/或管理与调节GPR119受体相关的疾病、紊乱、综合征或病况的方法。
• DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS
  申请人：Blair Brooke

  公开号：US20130245041A1

  公开（公告）日：2013-09-19

  In one aspect, the invention relates to compounds having the formula: wherein: Ar, Z, R 3 , R 4 and R 5 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT 1 receptor antagonist activity and neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

  在某个方面，本发明涉及具有以下式子的化合物：其中：Ar，Z，R3，R4和R5如规范中定义，或其药学上可接受的盐。这些化合物具有AT1受体拮抗活性和肽酶抑制活性。在另一个方面，本发明涉及包含这些化合物的制药组合物，使用这些化合物的方法以及制备这些化合物的过程和中间体。
• BICYCLIC GPR119 MODULATORS
  申请人：Thotapally Rajesh

  公开号：US20130245000A1

  公开（公告）日：2013-09-19

  The present invention relates to compounds of Formula (I) that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of GPR119 receptor activity. The invention also relates to the process for preparation of the compounds, pharmaceutical compositions thereof. The invention further relates to methods of treating, preventing and/or managing diseases, disorders syndromes or conditions associated with the modulation of GPR119 receptor by using either alone or in combinations of Formula (I).

  本发明涉及化合物(I)的使用，该化合物对于治疗、预防和/或管理与GPR119受体活性调节相关的疾病、紊乱、综合症或病况是有用的。本发明还涉及该化合物的制备过程、制药组合物。本发明还涉及使用化合物(I)单独或与其他化合物联合治疗、预防和/或管理与GPR119受体活性调节相关的疾病、紊乱、综合症或病况的方法。
• US8822522B2
  申请人：——

  公开号：US8822522B2

  公开（公告）日：2014-09-02
• US9000175B2
  申请人：——

  公开号：US9000175B2

  公开（公告）日：2015-04-07